JNJ has only been above $100 for a couple of days. Certainly it was above $100 previously, and for some time, but until it can maintain $100+ for more than a month at a time, you won't be seeing a split (not that a split will mean anything to the stock in any event.)
It was only a matter of time before a big pharmaceutical company jumped in on this miracle drug. The discovery by Geron of the immortal nature of cells lead to this imetetstat drug. Not only did they prove that an eternal being created all cells, but they are on the way to curing cancers.
Sentiment: Strong Buy
you sound like a new investor. Splits don't mean a thing- if you like the company just buy it.
Please do a 2-1 stock split as soon as possible.
To shut up the posters on this board who insist that having 200 shares of a stock at $50.00 paying a dividend of .35 a quarter, is somehow superior to having 100 shares of a stock at $100.00 paying a dividend of .70 a quarter.
"buy under $90" Really. Sounds like that may be a long wait. In the mean time you are loosing on valuable dividends.
even without Olysio, JNJ would be $110 if not for the general selloff. Olysio accounts for just a minor part of JNJ's profit picture. Lets not get 'hung up on only one facet of JNJ's success.
I'm have to agree with chickenguy_nc here.
As a 'long time share holder' you should know this.
JNJ has raised the dividend every year for the last 51 years!!
Bookmark this site & you won't have to ask in the future
Geron (GERN) Stock Surges Following Johnson & Johnson Licensing Deal
BY Andrew Meola Follow |
11/17/14 - 10:40 AM EST |
NEW YORK (TheStreet) -- Shares of Geron (GERN) surged 11.23% to $3.07 in morning trading Monday after the company announced late last week it had licensed its blood disorder drug imetelstat to Johnson & Johnson (JNJ) .
Geron said Janssen Biotech, whose parent company is Johnson & Johnson, agreed to pay $35 million to Geron upfront. Geron could receive up to $900 million additionally if it reaches certain regulatory and sales milestones. Geron would also receive royalties on imetelstat's sales.
Geron designed imetelstat to treat myelofibrosis, a disorder in which abnormal blood cells accumulate in bone marrow to form thick scar tissue that causes healthy blood cells to produce more slowly.
Thank you again Janssen and JNJ for believing that little known Geron Corp has developed a proven cancer cure. Your partnership along with $935 million dollars ensures GERN will have the needed assets to bring Imetelstat to market.
GERN stock is now well on its way to history. I hope all JNJ investors get in on the ground floor..
Analysts are focused on the possibility of a decrease in sales of ONE DRUG, Olysio. Never mind that JNJ has at least a dozen other drugs that will grow more than enough to take up the slack. That's part of the strength of JNJ. This is a good buying opportunity as JNJ will be back around $106-$108 by January.
Sentiment: Strong Buy